Found 66 matching trials
Administration of Virus-Specific Cytotoxic T-Lymphocytes PHASE1 The main purpose of this study is to see if these T-lymphocytes are safe. T...
Show More Location
National Institute of Health (NIH)
Learn More & Join Trial
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases PHASE1 Patients have a type of a lymph node cancer called lymphoma, a tumor of the...
Show More Location
Houston Methodist Hospital
Learn More & Join Trial
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) PHASE1 BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodig...
Show More Location
University of California San Francisco
Learn More & Join Trial
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies PHASE2 This is a Phase II trial to evaluate the efficacy and safety of human leuko...
Show More Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT PHASE1 Subjects are having a bone marrow or SCT for either a type of cancer of the...
Show More Status
Active Not Recruiting
Location
Houston Methodist Hospital
Learn More & Join Trial
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies N/A The primary objective of this protocol is to provide expanded access to tab...
Show More Status
No Longer Available
Location
Multiple Locations
Learn More & Join Trial
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer. PHASE1 In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-C...
Show More Location
First Affiliated Hospital of Henan University of Science and Technology
Learn More & Join Trial
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma PHASE1 RATIONALE: Biological therapies use different ways to stimulate the immune ...
Show More Location
Penn State Cancer Institute at Milton S. Hershey Medical Center
Learn More & Join Trial
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation PHASE1 To assess the safety and biological efficacy of therapeutically administere...
Show More Location
Westmead Hospital
Learn More & Join Trial
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer PHASE1 This study study aims to elucidate the immune responses to a shared antigen...
Show More Location
Washington University School of Medicine
Learn More & Join Trial